相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Lumasiran: First Approval
Lesley J. Scott et al.
DRUGS (2021)
A report from the European Hyperoxaluria Consortium (OxalEurope) Registry on a large cohort of patients with primary hyperoxaluria type 3
Cristina Martin-Higueras et al.
KIDNEY INTERNATIONAL (2021)
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
Sander F. Garrelfs et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Patients with primary hyperoxaluria type 2 have significant morbidity and require careful follow-up
Sander F. Garrelfs et al.
KIDNEY INTERNATIONAL (2019)
Predictors of Incident ESRD among Patients with Primary Hyperoxaluria Presenting Prior to Kidney Failure
Fang Zhao et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2016)
Data from a large European study indicate that the outcome of primary hyperoxaluria type 1 correlates with the AGXT mutation type
Giorgia Mandrile et al.
KIDNEY INTERNATIONAL (2014)
Primary Hyperoxaluria
Pierre Cochat et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Liver cell transplantation in severe infantile oxalosis-a potential bridging procedure to orthotopic liver transplantation?
Bodo B. Beck et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment
Pierre Cochat et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2012)
Genotype-phenotype correlation in primary hyperoxaluria type 1: the p.Gly170Arg AGXT mutation is associated with a better outcome
Jerome Harambat et al.
KIDNEY INTERNATIONAL (2010)
Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1
Sonia Fargue et al.
KIDNEY INTERNATIONAL (2009)
Alanine-glyoxylate aminotransferase-deficient mice, a model for primary hyperoxaluria that responds to adenoviral gene transfer
Eduardo C. Salido et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
分享论文
